Partial
Partially Aligned
Patient Risk:
Moderate
Summary
Some mechanistic and dosing elements are supported (MT1/MT2 agonism; 20 mg one hour before bedtime at the same time each night; effect may take weeks/months), but multiple claims are more specific than the provided label (notably blindness-specific indication/etiology and several mechanistic/clinical-effect phrasings). Several safety- and counseling-related claims cannot be verified because the provided label sections contain headings without corresponding content.
Category Scores
Accurate Statements
Tasimelteon targets melatonin receptors MT1 and MT2.
12.1 Mechanism of Action: tasimelteon is an agonist at melatonin MT1 and MT2 receptors.
Tasimelteon is taken once daily (20 mg one hour before bedtime, at the same time every night).
2.2 Recommended Dosage: 20 mg one hour before bedtime, at the same time every night.
Because of individual differences in circadian rhythms, drug effect may not occur for weeks or months.
2.2 Recommended Dosage: effect may not occur for weeks or months.
Unsupported Statements
Tasimelteon is a prescription medicine used to treat non-24-hour sleep-wake disorder (non-24) in adults who are blind.
1.1 indicates Non-24 in adults but the provided label section does not specify that patients are blind.
Non-24 in blind adults is tied to the body’s circadian rhythm not syncing to the normal light-dark cycle.
No provided label text describes blindness-specific etiology or light-dark desynchronization.
Tasimelteon is designed to act on the brain’s circadian rhythm system.
12.1 supports melatonin MT1/MT2 agonism thought to be involved in control of circadian rhythms, but does not support the more specific phrasing 'designed' and 'brain' system in the provided text.
By acting on melatonin receptors, tasimelteon helps shift and stabilize the sleep-wake timing in people whose internal clocks are not properly synchronized.
12.1 supports involvement in control of circadian rhythms via MT1/MT2 agonism, but the provided text does not explicitly support 'shift and stabilize' or 'internal clocks not properly synchronized' phrasing.
Tasimelteon is typically scheduled at the same time each day to support consistent circadian signaling.
2.2 supports dosing 'at the same time every night' but the provided label does not explicitly connect this to 'consistent circadian signaling.'
The goal of treatment for non-24 is to re-align the sleep-wake cycle to a regular pattern.
No provided label text states a treatment goal with this wording.
Common side effects of tasimelteon can include headache and nausea.
The provided label shows a '6 Adverse Reactions' heading but contains no adverse reaction content in the supplied text.
Fatigue or sleep-related complaints can also be possible with tasimelteon depending on the individual and timing.
The provided label shows a '6 Adverse Reactions' heading but contains no adverse reaction content in the supplied text.
Patients should discuss risks and tolerability with a clinician, especially if they have other medical conditions or take interacting drugs.
5 Warnings and Precautions and 7 Drug Interactions are listed as headings without provided content; no counseling language is present in the supplied text.
DrugPatentWatch.com compiles patent and exclusivity signals for tasimelteon.
Not addressed in the provided FDA label text.
The most reliable sources for exact tasimelteon product information ... are the FDA label or the manufacturer’s prescribing information ...
This is general guidance and not addressed in the provided FDA label text.
Contradictions
Important Omissions
Boxed warning/contraindications content and other safety details cannot be verified because Section 4 (Contraindications) is not included in the provided 'available label sections' text, and Section 5/6/7 content is missing. Claims related to risks/side effects/interactions were not supported.
Importance:
High
Safety Assessment
Potential Patient Risk:
Moderate
Multiple dosing-related and mechanistic claims are partially supported, but several safety-related claims (specific side effects; counseling about interacting drugs/other conditions) are unsupported due to missing adverse reaction/warnings/interaction content in the provided label text. Additionally, the blindness-specific patient population claim is not substantiated in the provided indication text.
Regulatory Assessment
| On Label |
No |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
Medium |
Recommendation
Partially Aligned
Primary Issue
Several claims add specificity beyond the provided FDA label text (blindness-specific population/etiology; 'shift and stabilize'/'internal clocks' phrasing) and safety/counseling claims are unsupported because the provided label sections lack content.
Suggested Improvement
Restrict statements to what is explicitly supported in the provided label text (adult Non-24 indication without blindness limitation; MT1/MT2 agonism; dosing timing; effect may take weeks/months). Remove or clearly qualify claims about blindness-specific etiology, explicit treatment goals, and specific side effects/counseling/interactions unless matching supported label content is provided.